At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 111 enrolled
Drug / intervention
Paclitaxel +2 moredrug
Likely dose
300mg DKN-01from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
In Brief
A Phase 2 clinical trial evaluating Paclitaxel, 300mg DKN-01, and 1 other intervention for Endometrial Cancer and 3 related conditions. Completed, enrolled 111 participants across 17 sites.
Detailed Summary
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartMar 2018
Primary CompletionSep 2020
Study CompletionJan 2021
TodayJul 2026
First PostedJan 10, 2018
Enrollment StartMar 5, 2018
Primary CompletionSep 9, 2020
Study CompletionJan 27, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.5 years ago
Interventions
Paclitaxeldrug
Administered by IV infusion
300mg DKN-01drug
Administered by IV infusion
600mg DKN-01drug
Administered by IV infusion